Researchers from The University of Texas Medical Branch at Galveston have found that while the 30-day readmission
    rate for patients with chronic obstructive pulmonary disease has decreased, the mortality rate has increased.
The UTMB researchers analyzed data from a nationwide cohort of more than 4.5 million Medicare beneficiaries with COPD
    to learn more about the impact of a federal program designed to reduce the number of people needing hospitalization
    within the first 30 days after being released from the hospital for a COPD-related illness.
The findings, said first author Daniel Puebla Neira, UTMB Pulmonary & Critical Care Fellow, are concerning in
    that some hospitals, in seeking to avoid financial penalties by reducing readmissions, may inadvertently affect
    minority and disadvantaged patients – people who may have a higher risk of dying.
The findings are currently available in the American Journal of Respiratory and Critical
        Care Medicine.
COPD is the third leading cause of death in the United States, affecting 12.7 million Americans and about 800,000
    patients are hospitalized with COPD each year. Of these, 1 in 5 patients are readmitted after being discharged from
    the hospital, which is linked with poor outcomes and costs about $13 billion annually. In order to improve the
    patients’ long-term health and control rising healthcare costs, the Patient Protection and Affordable Care Act
    created the Hospital Readmissions Reduction Program, or HRRP, in March 2010. The program began penalizing hospitals
    for higher than expected 30-day readmissions rates for non-COPD conditions.
Since the creation of the program, hospitals have reduced their readmission rates. However, it was also suspected
    that the program may be associated with an increase in the 30-day risk of post-discharge mortality rates for some
    groups of patients currently participating in the program.
“The benefits of the HRRP to improve health, prevent unnecessary hospitalizations, and control Medicare
    spending have been widely discussed and debated,” said senior author Dr. Gulshan Sharma, director of the
    Division of Pulmonary Critical Care & Sleep Medicine. “An important concern is the current penalties for
    readmission do not to take into consideration the impact on mortality. Reducing readmissions may inadvertently
    affect minority and disadvantaged patients. These patients are not only at higher risk for readmission, they may
    also be at higher risk of dying.”
The research team analyzed data from 4,587,542 Medicare fee-for-service beneficiaries with COPD who were 65 years and
    older. The study period from 2006 to 2017 covers the creation of HRRP and the introduction of COPD to the program.
    The data revealed that while the program does decrease the 30-day hospital readmission rate, it also significantly
    increases in the risk-standardized 30-day post-discharge mortality rates across the nation.
“Further research is needed to confirm our findings and identify factors contributing to the increased
    mortality seen in patients with COPD in the Centers for Medicare & Medicaid Services readmission reduction
    program,” said Puebla Neira.
Others authors include UTMB’s En Shuo Hsu, Yong-Fang Kuo and Kenneth Ottenbacher.